Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy
Publication in refereed journal


香港中文大学研究人员 ( 现职)

姚凯诗教授 (药剂学院)

全文

数位物件识别号 (DOI) http://dx.doi.org/10.1517/14656566.2015.1013028

引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/6WOS source URL

其它资讯

摘要Introduction: Clopidogrel is an antiplatelet agent widely prescribed for acute coronary syndrome (ACS), and it is activated by the CYP enzyme system to active metabolite. CYP2C19 loss-of-function (LOF) allele(s) affect the responsiveness of clopidogrel, but not the new antiplatelet agents (prasugrel and ticagrelor). We reviewed the pharmacoeconomic studies on genotype-guided use of new antiplatelet agents.

着者Jiang MH, You JHS
期刊名称EXPERT OPINION ON PHARMACOTHERAPY
详细描述Early Online.
出版年份2015
月份4
日期1
卷号1http://aims.cuhk.edu.hk/converis/portal/Publication/6
期次5
出版社INFORMA HEALTHCARE
页次771 - 779
国际标準期刊号14http://aims.cuhk.edu.hk/converis/portal/Publication/65-http://aims.cuhk.edu.hk/converis/portal/Publication/65http://aims.cuhk.edu.hk/converis/portal/Publication/6http://aims.cuhk.edu.hk/converis/portal/Publication/6
电子国际标準期刊号1744-7http://aims.cuhk.edu.hk/converis/portal/Publication/6http://aims.cuhk.edu.hk/converis/portal/Publication/6http://aims.cuhk.edu.hk/converis/portal/Publication/6
语言英式英语

关键词clopidogrel; cost-effectiveness; CYP2C19; pharmacogenetics; prasugrel; ticagrelor
Web of Science 学科类别Pharmacology & Pharmacy